TABLE

Demographics and imaging results

Patient No./Sex/Age (y)	Histologic Diagnosis	Tumor Location	USPIO	Iron Uptake	T1 Signal Intensity Change	T2 Signal Intensity Change
1/F/48	Metastatic large cell carcinoma	Cerebellum	Ferumoxides	−	−	−
2/M/46	Anaplastic oligodendraglioma	R temporoparietal	Ferumoxides	+^*	+	−
3/F/53	Meningioma	L frontal	Ferumoxides	−	−	−
4/M/54	Gliblastoma multiforme	L thalamus, parietal	Ferumoxtran-10	+	+	+
5/M/55	Anaplastic oligodendraglioma	L temporal	Ferumoxtran-10	+^†	+	+
6/M/54	Oligodendroglioma	L frontotemporal	Ferumoxtran-10	−	−	−
7/F/47	Hamartoma	L temporal	Ferumoxtran-10	+^*	+	−
8/F/30	Medulloblastoma	Cerebellum	Ferumoxtran-10	+^†	+	+
9/M/58	Anaplastic oligodendraglioma	R temporoparietal	Ferumoxtran-10	+^†	+	+
10/M/55	Squamous cell carcinoma	Nasopharynx with skull base invasion	Ferumoxtran-10	+	+	+
11/M/50	Squamous cell carcinoma	Nasopharynx with skull base invasion	Ferumoxtran-10	+	+	+
12/F/42	Meningioma	L petroclival	Ferumoxtran-10	+^†	+	+
13/M/57	Oligodendroglioma	R parietal	Ferumoxtran-10	−	−	−
14/M/55	Anaplastic glioma	L temporal	Ferumoxtran-10	+^*	+	−
15/F/54	Glioblastoma multiforme	R temporoparietal	Ferumoxtran-10	+	+	+
16/F/66	Glioblastoma multiforme	R frontal	Ferumoxtran-10	+^†	+	+
17/F/57	Anaplastic oligodendraglioma	R frontal	Ferumoxtran-10	+^†	+	+
18/M/54	Pituitary adenoma	Intra- and suprasellar	Ferumoxtran-10	+	+	+
19/M/39	Glioblastoma multiforme	L fronto-opercular	Ferumoxtran-10	+	+	+
20/M/46	Anaplastic oligodendraglioma	R posterior temporal	Ferumoxtran-10	+^†	+	+

Note.—L indicates left; R, right; +, yes; −, no.
* Iron accumulation was only minimal compared with gadolinium enhancement.
† Ferumoxtran enhancement as measured with ROI (see Methods) was regionally more prominent than gadolinium enhancement.